The groundbreaking success of Viagra undeniably transformed the pharmaceutical landscape, but placing funds in companies primarily reliant on off-patent versions presents a challenging picture. While early returns were substantial, the expiration of patents and the rise of cheaper alternatives have diminished the customer base. Consequently, a thor